GLAXF News and Press, GlaxoSmithKline Plc From 03/11/24

2024-03-11 08:22:37 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-02-23 16:52:40 ET Summary Moderna, Inc.'s market share for the Spikevax vaccine is increasing, but the company faces a tough 2024 with expected revenue slumps. The new respiratory vaccine has questioned efficacy and is late to market, potentially impacting the sales potential...

2024-02-16 07:30:00 ET Summary Dividend income from my taxable account totaled $1,013.35. This represents a 12.1% increase in passive income compared to January 2023. The markets may swing wildly from week to week and month to month, but dividends are seemingly more stable, re...

2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...

2024-02-15 02:45:38 ET Summary GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK’s f...

2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-01-31 08:34:05 ET GSK plc (GSK) Q4 2023 Earnings Conference Call January 31, 2024 06:00 AM ET Company Participants Nick Stone - Head, Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Ch...

2024-01-26 17:56:59 ET Summary GSK's Q4 2023 and full-year 2023 earnings released later this month are expected to continue showing strength, especially with the successful launch of Arexvy, its respiratory disease vaccine. However, there are risks ahead too, as Zantac hearings ar...

2024-01-15 06:46:00 ET Summary This is hardly breaking news, but as we head into 2024, the UK stock market remains one of the most attractive markets for dividend investors on the planet. As has long been the case, these high-yield stocks mostly operate in a handful of sectors tha...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...